Evidence map›Paper›PMID 37171518›Full record

ArticlePharmacological reports : PR2023

Nano-antibiotic based on silver nanoparticles functionalized to the vancomycin-cysteamine complex for treating Staphylococcus aureus and Enterococcus faecalis.

Thaís S Veriato, Inglid Fontoura, Luciane D Oliveira, Leandro J Raniero, Maiara L Castilho

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological reports : PR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Thaís S VeriatoBionanotechnology Laboratory, Research & Development Institute, University of Vale do Paraíba, São José dos Campos, São Paulo, 12244000, Brazil.
Inglid FontouraBionanotechnology Laboratory, Research & Development Institute, University of Vale do Paraíba, São José dos Campos, São Paulo, 12244000, Brazil.
Luciane D OliveiraDepartment of Biosciences and Oral Diagnosis, Institute of Science and Technology, Sao Paulo State University, São José dos Campos, São Paulo, 12245-000, Brazil.
Leandro J RanieroNanosensors Laboratory, Research & Development Institute, University of Vale do Paraíba, São José dos Campos, São Paulo, 12244000, Brazil.
Maiara L CastilhoBionanotechnology Laboratory, Research & Development Institute, University of Vale do Paraíba, São José dos Campos, São Paulo, 12244000, Brazil. mcastilho@univap.br.ORCID http://orcid.org/0000-0002-8410-0302

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 302994/2018-4Conselho Nacional de Desenvolvimento Científico e Tecnológico 427602/2018-1Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88887.495398/2020-00Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/23898-6
6 · The paper itself

Abstract

backgroundBacterial resistance is defined as a microorganism's capacity to develop mechanisms for resisting a determined antimicrobial. Gram-positive bacteria, such as Staphylococcus aureus (S. aureus) and Enterococcus faecalis (E. faecalis), are internationally recognized among the isolates with this resistance profile. In this context, the demand for new medicines has risen, and silver nanoparticles (AgNPs) have been highlighted, especially for their anti-bacterial effects. To develop a nano-antibiotic for treating these Gram-positive strains, we herein report synthesizing and characterizing a nano-antibiotic based on AgNPs functionalized with the complex vancomycin-cysteamine.

methodsAgNPs were produced using the bottom-up methodology and functionalized with vancomycin modified by the carbodiimide chemistry, forming Ag@vancomycin. Susceptibility tests were performed using S. aureus and E. faecalis strains to assess the bacteriostatic and bactericidal potential of the developed nano-antibiotic.

resultsFourier transform infrared spectroscopy measurements showed the efficacy of vancomycin chemical modification, and the characteristic bands of AgNPs functionalization with the antibiotic. The increase in the nano-antibiotic average hydrodynamic diameter observed by dynamic light scattering proved the presence of vancomycin at the surface of AgNPs. The data from the minimum inhibitory concentration and minimal bactericidal concentration assays tested on standard and clinical planktonic strains of S. aureus and E. faecalis presented excellent performance.

conclusionThe results indicate the promising development of a new nano-antibiotic in which the functionalization potentiates the bacteriostatic action of AgNPs and vancomycin with greater efficacy against Gram-positive strains.

Indexed as

Anti-Bacterial AgentsMetal NanoparticlesCysteamineEnterococcus faecalisMicrobial Sensitivity TestsSilverStaphylococcus aureusVancomycinAnti-Bacterial AgentsCysteamineSilverVancomycinEnterococcus faecalisSilver nanoparticlesStaphylococcus aureusVancomycin

Identifiers

PMID37171518
PMCPMC10176295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.